Yulei Wang - Senior Fellow, Translational Medicine-Oncology, Translational Medicine

Yulei Wang

Senior Fellow, Translational Medicine-Oncology, Translational Medicine

Postdoc Mentor
"Making impacts on science and making impacts on patients. Being able to do both as a scientist at Genentech is incredible rewarding."
Years at Genentech
Awards & Honors

I joined Genentech in 2011. As a Senior Principal Scientist in the Department of Oncology Biomarker, I lead the translation and reverse translation studies in liver cancer and ovarian cancer disease areas as well as global combination immunotherapy development. By integrating cancer genomics, digital pathology, ctDNA and single cell multi-omics in clinical biomarker studies, my team has gained novel insights into potential mechanisms of response and resistance to cancer immunotherapies.

Postdoctoral Mentor

Becoming a postdoc mentor has been the most exciting and rewarding experience for me. The postdoc program provides us an excellent opportunity to gain insights into disease biology and mechanism of response and resistance in drug development via cutting-edge translation and reverse translation research.

Summary of Publications: PDF

Featured Publication

Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer.

Cancer Cell. 2021 Jul 12;39(7):928-944.e6. doi: 10.1016/j.ccell.2021.04.004. Epub 2021 May 6.

Hornburg M, Desbois M, Lu S, Guan Y, Lo AA, Kaufman S, Elrod A, Lotstein A, DesRochers TM, Munoz-Rodriguez JL, Wang X, Giltnane J, Mayba O, Turley SJ, Bourgon R, Daemen A, Wang Y.

Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment.

Immunol Rev. 2021 Jul;302(1):241-258. doi: 10.1111/imr.12982. Epub 2021 Jun 1.

Desbois M, Wang Y.

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.

2020 Nov 5;11:598877. doi: 10.3389/fimmu.2020.598877.

Hack SP, Zhu AX, Wang Y.

Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer.

Nat Commun. 2020 Nov 4;11(1):5583. doi: 10.1038/s41467-020-19408-2.

Desbois M, Udyavar AR, Ryner L, Kozlowski C, Guan Y, Dürrbaum M, Lu S, Fortin JP, Koeppen H, Ziai J, Chang CW, Keerthivasan S, Plante M, Bourgon R, Bais C, Hegde P, Daemen A, Turley S, Wang Y.

Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level. J Mol Diagn.

2020 Jun;22(6):770-781. doi: 10.1016/j.jmoldx.2020.02.013. Epub 2020 Apr 2.

Lu S, Chang CJ, Guan Y, Szafer-Glusman E, Punnoose E, Do A, Suttmann B, Gagnon R, Rodriguez A, Landers M, Spoerke J, Lackner MR, Xiao W, Wang Y.

High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.

J Mol Diagn. 2017 Nov;19(6):921-932. doi: 10.1016/j.jmoldx.2017.08.001. Epub 2017 Sep 1.

Guan Y, Mayba O, Sandmann T, Lu S, Choi Y, Darbonne WC, Leveque V, Ryner L, Humke E, Tam NWR, Sujathasarma S, Cheung A, Bourgon R, Lackner MR, Wang Y.

Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.

Clin Cancer Res. 2015 Jul 1;21(13):2941-51. doi: 10.1158/1078-0432.CCR-14-3111. Epub 2015 Apr 2.

Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C, Lu S, Fuentes E, Huw LY, Lackner MR, Fu L, Amler LC, Bais C, Wang Y.

High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

Clin Cancer Res. 2014 Apr 15;20(8):2080-91. doi: 10.1158/1078-0432.CCR-13-3114. Epub 2014 Feb 26.

Bourgon R, Lu S, Yan Y, Lackner MR, Wang W, Weigman V, Wang D, Guan Y, Ryner L, Koeppen H, Patel R, Hampton GM, Amler LC, Wang Y.